| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 17,589,978 | 10,461,971 | ||
| Restricted cash | 1,352,975 | 1,352,975 | ||
| Prepaid expenses and deposits | 1,126,724 | 1,278,589 | ||
| Other receivables | 1,665,153 | 1,674,335 | ||
| Total current assets | 21,734,830 | 14,767,870 | ||
| Total assets | 21,734,830 | 14,767,870 | ||
| Accounts payable and accrued liabilities | 1,664,647 | 2,267,871 | ||
| Related party payable | 328,315 | 656,631 | ||
| Deferred revenue | 1,352,975 | 1,352,975 | ||
| Total current liabilities | 3,345,937 | 4,277,477 | ||
| Total liabilities | 3,345,937 | 4,277,477 | ||
| Common stock, 0.001 par value, 30 million shares authorized, 16.7 million and 10.7 million shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively (see note 8) | 16,672 | 11,313 | ||
| Additional paid-in capital | 475,849,809 | 465,958,006 | ||
| Accumulated deficit | -457,477,588 | -455,478,926 | ||
| Total stockholders' equity | 18,388,893 | 10,490,393 | ||
| Total liabilities and stockholders' equity | 21,734,830 | 14,767,870 | ||
Marker Therapeutics, Inc. (MRKR)
Marker Therapeutics, Inc. (MRKR)